Akrikhin expands deal with Merck & Co

8 August 2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck & Co (NYSE: MRK) within the scope of Merck’s product manufacturing localization strategy in Russia.

Last year, the companies signed an agreement on the production of six key Merck brands in various pharmaceutical forms and dosages at Akrikhin manufacturing site, used for treating cardiovascular, dermatologic and allergenic diseases, as well as for anesthesia applications (The Pharma Letter July 12, 2012). Now, as the second wave of the contract, Akrikhin will start to manufacture five additional Merck brands important for local health care system.

Akrikhin’s manufacturing site will be dedicated to the release of Merck’s drugs for type 2 diabetes mellitus (sitagliptin, Januvia: sitagliptin + metformin, Janumet), bronchial asthma and allergic rhinitis (montelukast, Singulair), invasive mycoses (posaconazole, Noxafil) as well as the hypolipidemic drug (ezetimibe, Ezetrol). Several product dosages and different pharmaceutical forms (tablets and suspension) will be manufactured.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK